ex vivo Gp91phox-transduced autologous CD34+ hematopoietic stem cell therapy (ImmunoVec)

N/A

Report date: 2025/01/26 19:33:02

Base Information

Drug Nameex vivo Gp91phox-transduced autologous CD34+ hematopoietic stem cell therapy (ImmunoVec)
Drug Alias Nameex vivo Gp91phox stem cell-based gene therapy (ImmunoVec)ex vivo NADPH oxidase 2 stem cell-based gene therapy (ImmunoVec)ex vivo NADPH oxidase 2-transduced autologous CD34+ hematopoietic stem cell therapy (ImmunoVec)
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Hematopoietic stem cells therapy
Mechanisms of ActionCYBB gene stimulants
TargetsNADPH Oxidase 2
Therapy Area/IndicationsGranulomatous Disease, Chronic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesImmunoVec Inc
China Registration ClassN/A

Develop Information

Active CompaniesImmunoVec Inc
Inactive CompaniesN/A
Active IndicationsGranulomatous Disease, Chronic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A